7th Eurasian Hematology Oncology Summit

 

7th Eurasian Hematology Oncology Summit
Avatar

How I Treat Mantle Cell Lymphoma in 2020: Induction Options, ASCT, and Combining Targeted Agents in Relapse/Refractory

By 7th Eurasian Hematology Oncology Summit FEATURING Charles A. Schiffer
By 7th Eurasian Hematology Oncology Summit FEATURING Charles A. Schiffer
0 views
July 24, 2020
Comments 1
Login to view comments. Click here to Login

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Featured Video

24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi
Lymphoma
14:50
7th Eurasian Hematology Oncology Summit

How I Treat Follicular Lymphoma in 2020: Rituximab vs. WW Strategy, …

Feat. G. Gaidano
19:51
7th Eurasian Hematology Oncology Summit

How I Treat DLBCL in 2020: Can Radiotherapy Be Omitted in PET Era? I…

Feat. U. Vitolo
23:29
7th Eurasian Hematology Oncology Summit

2020 Update on IO in R/R cHL: Is Long-Term Therapy w/ Nivo Feasible …

Feat. T. Tuglular
15:27
7th Eurasian Hematology Oncology Summit

How I Treat HL in 2020: What Is the Role of PET-Adapted Strategies? …

Feat. C. Gisselbrecht
21:20
7th Eurasian Hematology Oncology Summit

How I Treat Mantle Cell Lymphoma in 2020: Induction Options, ASCT, a…

Feat. C. Schiffer